文献速递神经头颈MR

进行性多灶性白质脑病:HIV感染患者的MRI表现更接近利妥昔单抗相关PML而非那他珠单抗相关PML

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
PubMed 文献 · Eur Radiol · 2020-11-06

该回顾性多中心研究分析了72例确诊PML患者的脑MRI,其中那他珠单抗治疗32例、利妥昔单抗治疗20例、HIV感染20例。结果显示利妥昔单抗相关PML的影像特征不同于那他珠单抗相关PML,而与HIV相关PML更接近;那他珠单抗相关PML表现出更多炎症征象、血管周围分布「银河」征及更多皮层受累。

要点

  • 三种PML均累及U纤维,T2*加权序列呈低信号。
  • 那他珠单抗相关PML可见主病灶内或邻近点状微囊样表现、皮层受累及强化。
  • HIV与利妥昔单抗相关PML仅见轻度强化、点状表现及皮层受累。

关键影像表现/征象

  • 三种PML均累及U纤维,T2*加权序列呈低信号。
  • 那他珠单抗相关PML在主病灶内或邻近可见点状微囊样表现、潜在皮层受累及对比强化。
  • HIV与利妥昔单抗相关PML仅见轻度强化、点状表现及皮层受累。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection.

MATERIALS AND METHODS: In this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement.

RESULTS: The three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response.

CONCLUSION: Imaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML.

KEY POINTS: • Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies. • Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution "the milky way," and more cortex involvement than rituximab- and HIV-associated PML. • MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Alleg M, Solis M, Baloglu S, et al. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. Eur Radiol. 2020. PMID: 33155106. doi:10.1007/s00330-020-07362-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。